[
  {
    "ts": null,
    "headline": "Danaher: Biotech Strength And Cash Generation Reinforce A $250 Fair Value",
    "summary": "Read here for the latest Danaher stock analysis: buy rating, 10.5% upside, and growth driven by biotech. See if DHR stock's premium is justified.",
    "url": "https://finnhub.io/api/news?id=fe755ec78498a313cf775ccdacf38ccd73f82bf9ce3a9f93777a042fc2965757",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765341483,
      "headline": "Danaher: Biotech Strength And Cash Generation Reinforce A $250 Fair Value",
      "id": 137746584,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386963076/image_1386963076.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "Read here for the latest Danaher stock analysis: buy rating, 10.5% upside, and growth driven by biotech. See if DHR stock's premium is justified.",
      "url": "https://finnhub.io/api/news?id=fe755ec78498a313cf775ccdacf38ccd73f82bf9ce3a9f93777a042fc2965757"
    }
  }
]